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Genetic associations with lung function and COPD susceptibility implicate novel genes, biological 
pathways and druggable targets 
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Abstract 
Chronic Obstructive Pulmonary Disease (COPD) is characterised by reduced lung function in smokers 
and non-smokers and is currently the third leading cause of death globally. Through genome-wide 
association discovery in 48,943 individuals, selected from the extremes of the lung function 
distribution in UK Biobank, and follow-up in an additional 95,375 individuals, we increased the yield 
of independent genetic signals for lung function from 54 to 97. A genetic risk score was associated 
with COPD susceptibility in independent populations (P=5.6x10-49) and we observed a 3.7 fold 
difference in COPD risk between highest and lowest genetic risk score deciles in UK Biobank.  The 97 
signals show enrichment in pathways relating to development, elastic fibres and epigenetic 
regulation.  We also highlight targets for known drugs and compounds in development for COPD and 
asthma (genes in the inositol phosphate metabolism pathway and CHRM3) and describe targets for 
potential drug repositioning from other clinical indications. 
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Main text (2000-4000 words, excluding abstract, online methods, references and figure legends) 
 
Maximally attained lung function and subsequent lung function decline together determine the risk 
of developing Chronic Obstructive Pulmonary Disease (COPD)1,2. COPD, characterised by irreversible 
airflow obstruction and chronic airway inflammation, is the third leading cause of death globally3. 
Smoking is the primary risk factor for COPD but not all smokers develop COPD and more than 25% of 
COPD cases occur in never-smokers4. Patients with COPD exhibit variable presentation of symptoms 
and pathology, with or without exacerbations, with variable amounts of emphysema and with 
differing rates of progression. Although risk factors for COPD are known, including smoking and 
environmental exposures in early5,6 and later life, the causal mechanisms are not well understood7. 
Disease-modifying treatments for COPD are required7.  
Understanding genetic factors associated with reduced lung function and COPD susceptibility could 
inform drug target identification, risk prediction and stratified prevention or treatment. Previous 
genome-wide association studies (GWAS) of COPD identified several independent COPD-associated 
variants8-10 but the rate and scale of discovery has been limited by available sample sizes. Therefore 
we conducted a powerful GWAS for lung function, and followed up the robustly-associated variants 
in COPD case-control studies. This offered a reduced multiple testing burden, and therefore 
increased power, compared to undertaking a genome-wide association discovery in a COPD case-
control study.. Although previous GWAS have reported genome-wide significant associations with 
lung function11-16, there has not been a comprehensive study confirming the effect of these variants 
on COPD susceptibility. In this study, we hypothesised that: (i) undertaking GWAS of lung function of 
unprecedented power and scale would detect novel loci associated with quantitative measures of 
lung function; (ii) collectively these variants would be associated with the risk of developing COPD, 
and (iii) aggregate analyses of all novel and previously-reported signals of association, and the 
identification of genes through which their effects are mediated, would reveal further insight into 
biological mechanisms underlying the associations. Together these findings could provide potential 
novel targets17 for therapeutic intervention and pinpoint existing drugs which could be candidates 
for repositioning18 for the treatment of COPD. 
Results 
43 new signals for lung function 
For stage 1, genome-wide association analyses of forced expired volume in 1 second (FEV1), forced 
vital capacity (FVC) and FEV1/FVC were undertaken in 48,943 individuals from the UK BiLEVE study16 
who were selected from the extremes of the lung function distribution in UK Biobank (total 
n=502,682). From analysis of 27,624,732 variants, 81 independent variants associated with one or 
more traits with P<5x10-7 were selected for follow-up in stage 2, consisting of a further 95,375 
independent individuals from UK Biobank, the SpiroMeta consortium and UK Households 
Longitudinal Study (UKHLS) (Supplementary Table 1). No evidence of sample overlap between stage 
1 and stage 2 studies or between stage 2 studies was identified using LD score regression 
(Supplementary Table 2). Following meta-analysis of stage 1 and stage 2 results, 43 signals showed 
genome-wide significant (P<5x10-8) association with one or more of FEV1, FVC or FEV1/FVC 
(Supplementary Table 3 and Supplementary Figure 1). We report these 43 signals as novel 
7 
 
independent signals (Figure 1), almost doubling the number of confirmed independent genomic 
signals for lung function to 97 (Supplementary Table 4). Of the 43 novel signals, 33 represented 
novel loci whilst 10 were statistically independent signals (conditional P<5x10-7) within 500kb of 
another association signal. Based on an assumed heritability of 40%19,20 for each lung function trait, 
the novel signals explained 4.3% of the heritability of FEV1, 3.2% for FVC and 5.2% for FEV1/FVC 
bringing the total heritability explained by the 97 signals to 9.6%, 6.4% and 14.3%, respectively. The 
estimated effect sizes of lung function associated variants in children were correlated with those in 
adults (r=0.65, 73 variants with high imputation quality, Supplementary Figure 2). A genetic risk 
score based on these 73 variants, was also significantly associated with FEV1 and FEV1/FVC in 
children, (P=1.03x10-5 and P=1.27x10-8, respectively), but not with FVC (P=0.366). 
Using the stage 1 results, a 95% ‘credible set’ of variants (i.e. the set of variants that were 95% likely 
to contain the underlying causal variant, based on Bayesian posterior probability,) was defined for all 
(novel and previously reported) association signals for which this was feasible (67 signals, Figure 2, 
Supplementary Figures 3 and 4 and Supplementary Table 5); 13 of these signals were fine-mapped 
to <=10 plausible causal variants and for 63 of the 67 signals fine-mapped, the sentinel (lowest P 
value) variant was also the top ranked variant by posterior probability. In addition, by refining six 
MHC region association signals using imputation of classical alleles and amino acid changes, we 
identified the MHC class III gene HLA-DQB1 amino acid change 57 (alanine compared to non-alanine) 
as the main driver of signals in the MHC region for both FEV1 (P=5.71×10-13, Supplementary Figure 
5a) and FEV1/FVC (P=1.17×10-20, Supplementary Figure 5c) with secondary non-HLA gene signals in 
the MHC region remaining after conditioning on the HLA-DQB1 variant for ZKSCAN3 (FEV1, 
conditional P=1.26x10-9, Supplementary Figure 5b) and AGER (FEV1/FVC, conditional P=4.23x10-20, 
Supplementary Figure 5d), Supplementary Table 6).  
We identified that 29 of the lung function-associated signals had previously shown genome-wide 
significant association in GWAS of traits other than lung function or COPD. This included associations 
with inflammatory bowel disease (Crohn’s disease and/or ulcerative colitis, 3 signals) and height (9 
signals, 4 of which showed a consistent direction of effect on height and the lung function measure 
with which they were most strongly associated) (Supplementary Table 7). With the exception of 
KANSL116, there was no significant (P<5.15x10-4) association with smoking for any of the signals 
(Supplementary Table 8). The effect size estimates for the 43 sentinel variants were similar after 
excluding individuals with self-reported doctor-diagnosed asthma (Supplementary Figure 6). 
95 variants and COPD susceptibility 
The disease-relevance of lung function-associated variants has been questioned21. Therefore we 
tested association with COPD susceptibility for variants representing 95 of the 97 lung function 
associated signals in up to 19,354 COPD cases and 147,849 controls (data were unavailable for 
further study for the X-chromosome variant, rs7050036, and a rare variant, chr12:114743533) 
(Supplementary Table 9). Cases and controls comprised the COPD study at deCODE Genetics22, 
(COPD cases defined using spirometry, population-based controls excluding known cases, up to 
1,964 moderate-severe cases, up to 142,262 controls), three lung resection cohorts23-25 (COPD 
definition based on spirometry, 310 moderate-severe cases, 332 controls), four case-control studies 
employing post-bronchodilator spirometry8-10,26-29 (5,778 moderate-severe cases, 3,950 controls), 
two studies within which COPD was determined from electronic medical records30 (eMR, total 1,471 
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cases, 14,849 controls), and UK Biobank (COPD definition based on spirometry, 10,547 moderate-
severe31 cases, 53,948 controls). The UK BiLEVE component of the UK Biobank samples (9,497 
moderate-severe COPD cases) was used for GWAS discovery for lung function. If lung function 
associated variants are indeed associated with COPD susceptibility, then the magnitude of the effect 
estimates of novel variant COPD associations could be overestimated in UK BiLEVE due to winner’s 
curse bias. Therefore we compared COPD susceptibility effect sizes obtained using all UK Biobank 
data and excluding UK BiLEVE data for the 95 variants (Supplementary Figure 7); these results were 
broadly consistent. 
When tested individually, using a Bonferroni correction (5% threshold) for 95 tests (P<5.26x10-4), 56 
of the above 95 variants showed association with COPD susceptibility (25 of the 56 were novel 
signals, Supplementary Table 10). Using a risk score based on the available 95 sentinel variants or 
their best proxies, for the meta-analysis across all studies, the odds ratio per standard deviation 
change in risk score (~6 alleles) was 1.35 (meta-analysis P-value 5.06x10-221) and even when 
excluding UK BiLEVE, this association remained highly significant (P=5.56x10-49, Figure 3a, 
Supplementary Table 11). We observed considerable heterogeneity in effect estimates between the 
different COPD studies (I2=92%) which had different approaches to ascertainment of COPD cases and 
variable disease severity. Comparing the studies of moderate-severe COPD in UK Biobank (including 
UK BiLEVE) with well-characterised COPD case-control studies employing post-bronchodilator 
spirometry, we found broadly similar effect size estimates (OR=1.42 versus 1.36). Therefore, we 
undertook further modelling in UK Biobank, showing a gradation in susceptibility to moderate-
severe COPD across deciles of allelic risk score. The risk of moderate-severe COPD was more than 
three times higher in the top decile than the bottom decile (OR 3.71, 95% CI 3.33 to 4.12, Figure 3b). 
The estimated proportion of COPD cases attributable to allelic risk scores above the first decile 
(population attributable risk fraction) was 48.0% (95% CI 43.6 to 52.2).  
We tested association of individual variants and the 95-variant risk score with COPD exacerbations in 
subsets of individuals from UK Biobank, deCODE, four COPD case-control studies and two eMR 
studies (total 2,462 COPD exacerbation cases, 15,288 COPD non-exacerbation controls) and the Lung 
Health Study (100 exacerbation cases, 4,002 controls). There was no association of individual 
variants or genetic risk score with acute exacerbations of COPD (Supplementary Tables 12 and 13). 
To evaluate whether these variants showed disease-relevant associations in a non-European 
population, we studied 71 variants for which data were available in 7,116 COPD cases (20,919 
controls) and 5,292 exacerbation cases (1,824 controls) from the China Kadoorie Biobank cohort 
(CKB) (Supplementary Tables 10 to 13). The allelic risk score was associated with COPD susceptibility 
(P=4.2x10-6) suggesting some shared genetic contributions to COPD in European and East Asian 
descent populations. Thirty-nine of the variants showed a consistent direction of effect on COPD in 
European and Chinese samples and seven of these were significant (P<0.05). Two signals were 
significant after correction for multiple testing (Supplementary Table 10b). 
Implicated genes highlight pathways and druggable targets 
Gene expression and genotype data from lung, blood and multi-tissue resources were queried to 
identify whether the top variant at each signal, or its proxies, were significantly associated with 
changes in expression of any gene. Using this approach, and identification of deleterious variants 
within the signal (Supplementary Table 14), we implicated 234 genes with potentially causal effects 
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on lung function (Supplementary Table 15). These 234 genes were enriched (False Discovery Rate 
(FDR) ≤5%) in elastic fibre pathways and in “signalling events mediated by the Hedgehog family”, the 
latter including CDON at a novel signal.  We narrowed this group of 234 genes to 68 high-priority 
genes which were implicated via a deleterious variant or on stricter criteria for gene expression co-
localisation (sentinel variant and top expression variant r2≥0.9, Table 1). We found that the 68 high-
priority genes were overrepresented (FDR≤5%) among a number of gene ontology terms including 
SH3 domain binding, GTPase binding, actin binding and fibroblast migration (Supplementary Table 
16). Alternative approaches to pathway analyses, which instead use all genome-wide association 
results, supported previous reports of enrichment of histone and systemic lupus erythematosus 
pathways14-16 and additional autoimmune and inflammatory pathways (Supplementary Table 17). 
Tests for tissue-specific enrichment of lung function signals overlapping histone marks identified 
enrichment in fetal lung, fetal heart and fibroblasts (H3K4me1), and stomach smooth muscle 
(H3K4me1 and H3K4me3) (Supplementary Table 18).  
Approved drugs, or drugs in development, target the protein products of 7 of the 234 genes 
(Supplementary Table 19a). This includes 3 high-priority genes CHRM3, SLC6A4 and CRHR1. CHRM3 
and SLC6A4 were both implicated by novel signals and encode targets for drugs approved for the 
treatment of asthma and COPD (CHRM3, muscarinic acetylcholine receptor M3) and anxiety and 
depression (SLC6A4, serotonin transporter). CRHR1 encodes the corticotropin releasing factor 
receptor 1 which is a target for compounds in development for the treatment of anxiety, depression 
and irritable bowel syndrome. The other 4 genes include NDUFA12 (encoding an NADH 
dehydrogenase which is a target for metformin hydrochloride, primarily used to treat type 2 
diabetes) and ITK (encoding a tyrosine-protein kinase, a target for the cancer drug Pazopanib).  
Using STRING32 to find proteins that interact with the proteins encoded by the high priority genes, 
we highlighted further druggable targets (Supplementary Table 19b). These included the PI3-kinase 
p110-delta subunit (part of the inositol phosphate metabolism pathway with INPP5E and a target for 
compounds in development for the treatment of COPD and asthma), and matrix metalloproteinases 
1, 8 and 7 (targets for doxycycline, which is an antibiotic and anti-malarial).  
 Discussion  
 
In this study, the power gained by sampling from the extremes of a large biobank whilst retaining 
the power of a quantitative trait analysis, coupled with strategies to improve coverage of the 
genome and extensive follow-up, enabled a near-doubling of the number of signals of association 
with lung function identified to date. We further explored 95 variants, representing 43 novel signals 
and 52 previously reported signals, and showed that collectively these variants are strongly 
associated with COPD susceptibility. Allelic risk scores above the first decile accounted for >45% of 
COPD cases. 
Using functional evidence from eQTL studies and deleterious variants to link signals to genes, we 
identified that 41 of the lung function signals are also the strongest signals of association for 
expression of, or contain deleterious variants within, 68 genes (which we term “high-priority 
genes”). Amongst these, novel signals in or near FAM13A and ADAM19, both previously associated 
with lung function and COPD susceptibility9,33, reinforce evidence for FAM13A and ADAM19 
themselves being the drivers of those signals. There was significant enrichment amongst the 68 
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genes for SH3 domain (including ADAM19), GTPase and actin binding, and fibroblast migration, 
highlighting the potential importance of pathways relating to the cytoskeleton.  
The 68 genes identified as high-priority included genes at novel signals encoding targets for which 
there are approved drugs or drugs in development (Supplementary Table 19). Of note, the 
muscarinic acetylcholine receptor M3, encoded by CHRM3, is a well-characterised drug target for 
which many approved drugs exist, including for the treatment of asthma and obstructive lung 
disease. SLC6A4 encodes a serotonin transporter, a target for a number of drugs approved for 
treating depression and anxiety disorders, one of which (nortriptyline hydrochloride) has been 
trialed for use in inflammatory skin disorders (psoriasis and eczema); HTR4, a serotonin receptor, 
was identified in one of the earliest lung function GWAS13. INPP5E, identified as a high-priority gene 
for a novel signal of association with FVC (and FEV1) on chromosome 9, encodes inositol 
polyphosphate-5-phosphatase E, a component of the inositol phosphate metabolism pathway.  
Another component of the same pathway, phosphoinositide 3-kinase (PI3K) delta is a target of drugs 
under development for the treatment of a range of indications including COPD and asthma. 
Mutations in INPP5E cause ciliopathy (Joubert and MORM syndromes).  
Protective genetic variants that reduce the function or expression of a target protein, could be 
mimicked by drugs and so are of particular interest. The minor allele (MAF 17%) at the novel signal in 
FAM13A, was associated with decreased expression of FAM13A in lung tissue and reduced risk of 
COPD. This, together with recent evidence from a study of the Fam13a knockout mouse34,  suggests 
that pharmacological inhibition of FAM13A may be protective.  
Extending our pathway analyses to all 234 genes implicated by gene expression or deleterious 
variants, we observed enrichment of genes related to “signalling events mediated by the Hedgehog 
family” pathway. Hedgehog signalling plays a crucial role in early development.  Three members of 
this pathway, PTCH1, TGFB2 and HHIP, have been previously reported as likely causal genes 
underlying lung function association signals35. In this study, we additionally report PTHLH, encoding a 
parathyroid hormone-like hormone, and CDON¸ encoding a Hedgehog co-receptor, as likely causal 
genes (the latter at a novel signal). We show correlation (r=0.62) between variant effect size 
estimates in children and in adults, suggesting that many of these variants may act, at least in part, 
via effects on lung development. Elastic fibre pathways were over-represented; products of elastin 
degradation have been shown to be elevated during acute exacerbations of COPD 36,37. In addition, 
degradation of elastin by excess neutrophil-released elastase in the lung leads to emphysema in 
individuals with alpha-1 antitrypsin deficiency.  CARD9, another high-priority gene at a novel signal, 
encodes an adaptor protein involved in neutrophil recruitment in respiratory fungal infection38. 
Tissue-specific enrichment of lung function signals overlapping H3K4me1 was seen in stomach 
smooth muscle. Although comparable H3K4me1 data were not available for airway smooth muscle, 
similar findings have been reported previously for rectal smooth muscle39. 
The 17q21.31 inversion has previously been associated with lung function. Custom imputation of 
additional structural variation at the locus, along with eQTL evidence and deleterious variants in the 
gene, suggested that KANSL1 may drive the association. Amongst the novel signals reported in this 
study, SNPs in an intron of EEFSEC on chromosome 3 are correlated with expression of nearby gene 
RUVBL1. Both KANSL1 and RUVBL1 are members of histone modification complexes.  
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A novel signal on chromosome 20 (rs72448466), which showed association with FVC almost as 
strong as its association with FEV1, implicates the telomere gene, RTEL1, as a potential driver of the 
signal. Although rs72448466 was not the strongest eQTL for RTEL1 (r2=0.6 with the top eQTL 
variant), RTEL1 is of interest as it has recently been implicated in familial pulmonary fibrosis40. 
Variant rs72448466 has also been associated with inflammatory bowel disease, prostate cancer and 
atopic dermatitis. 
Six signals of association have been previously identified within the HLA region. Using a custom 
imputation approach, we identified the presence of alanine (compared to aspartic acid, valine or 
serine) at amino acid 57 in HLA-DQB1, as associated with decreased lung function and the main 
driver of signals in this region. The presence of alanine is also strongly associated with risk of type 1 
diabetes41. 
The three lung function traits we studied are correlated. In UK Biobank, the overall and genetic 
correlations were: 0.88 and 0.87 between FEV1 and FVC; 0.46 vs 0.35 between FEV1 and FEV1/FVC 
and; 0.038 and -0.17 between FVC and FEV1/FVC (transformed traits, as studied). One might expect 
variants showing strongest association with FEV1 and FEV1/FVC to be of greatest relevance for COPD. 
We show, however, that variants associated with one of these traits also tend to be associated with 
one of the other two lung function traits studied (for example, all but 2 signals for FVC are also 
associated (P<0.05) with FEV1 or FEV1/FVC, Supplementary Table 4). Although classification of COPD 
in UK Biobank was based on pre-bronchodilator spirometry, we have previously shown that this 
leads to minimal misclassification of moderate-severe (GOLD 2-4) COPD42. Our spirometry-based 
definition could exclude some COPD patients with mild airflow obstruction and include some 
patients with airflow obstruction but without symptoms. The effect size estimates for COPD 
associations could be influenced by differences in case ascertainment between the follow-up 
studies. Whilst winner’s curse bias could additionally affect estimates in the UK BiLEVE component 
of UK Biobank, we present results with and without UK BiLEVE samples and Figure 3b utilised 
weights only from follow-up studies. Notably, we found effect size estimates only slightly smaller in 
deeply-characterised COPD case-control studies than in UK Biobank (OR per SD change in allelic risk 
score 1.36 compared to 1.42). The lung function-associated variants we report were not associated 
with acute exacerbations of COPD. Although more powerful studies of exacerbations will be 
required, this suggests that different genetic mechanisms could underlie risk of acute exacerbations. 
A threshold of P<5x10-8 is a valid threshold for genome-wide significance in GWAS analyses of 
common variants43. Our genotyping and imputation strategy resulted in testing of up to 27 million 
variants of which 21.60 had MAF<5% and 18.2 had MAF<1%. Although all of our 43 signals were 
common, had we adopted a stricter threshold for genome-wide significance, for example, P<1x10-8 
(recommended in a recent report of significance thresholds in whole genome sequencing43), only 
two of our signals (rs10246303 and rs1698268) would not have reached significance. Thirty-nine of 
the 43 signals were additionally supported by statistically significant independent replication in stage 
2 (P<0.05/43, Supplementary Table 3). 
In summary, our study provides the most comprehensive evidence yet regarding genetic variants 
associated with lung function and their association with susceptibility to COPD, with a more than 
threefold difference in COPD risk between highest and lowest allelic risk score deciles. Whilst 
translation of GWAS findings can take some years and requires extensive additional work, selecting 
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genetically supported targets could double the drug development success rate17. The future clinical 
relevance of our findings include contributions towards understanding of disease pathogenesis, 
identification of drug targets for targeting or repositioning of drugs18, and potentially improved 
prediction of COPD or its subtypes. 
Online Methods  
Study Governance 
UK Biobank has ethical approval from the NHS National Research Ethics Service (Ref 11/NW/0382). 
Informed consent was obtained from all participants. All other studies were approved by an 
appropriate ethics committee or data protection authority (Supplementary Note). 
Stage 1 study sample selection 
A genome-wide discovery study for variants associated with lung function measures was performed 
in 48,943 individuals from the UK BiLEVE16 subset of UK Biobank (UK BiLEVE, stage 1). In brief, UK 
Biobank comprised 502,682 individuals of whom 275,939 were of self-reported European-ancestry 
and had ≥2 Forced Expired Volume in 1s (FEV1) and Forced Vital Capacity (FVC) measures 
(Vitalograph Pneumotrac 6800, Buckingham, UK) passing ATS/ERS criteria44. Based on the best 
(highest) available FEV1 measurement, 50,008 individuals were then selected from groups with 
extreme low (n=10,002), near-average (n=10,000) and extreme high (n=5,002) % predicted FEV1 
were selected from amongst never-smokers (total n=105,272) and the same numbers from amongst 
the heavy-smokers (mean 35 pack-years of smoking, total n=46,758). FEV1, FVC and FEV1/FVC 
distributions are summarised in Supplementary Figure 8. Genotyping was undertaken using the 
Affymetrix Axiom UK BiLEVE array16 and imputed to the 1000 Genomes Project Phase 145 and 
UK10K46,47 combined panel. A total of 27,624,732 imputed or directly genotyped autosomal variants 
with imputation quality (info) >0.5 and minor allele count (MAC) ≥ 3 were included in the analysis. In 
total, 48,943 unrelated individuals passed all quality control steps and were used in this analysis. 
Association testing and selection of signals from stage 1 for follow-up in stage 2 
Power calculations were undertaken using Quanto (http://biostats.usc.edu/Quanto.html) 
(Supplementary Figure 9). For stage 1, genome-wide association studies of FEV1, FVC and FEV1/FVC 
were undertaken separately in heavy-smokers and never-smokers and then meta-analysed for each 
trait. Linear regression of age, age2, sex, height, the first 10 principal components of genetic ancestry 
and pack years of smoking (in smokers) on each trait was undertaken and residuals were ranked and 
transformed to inverse normally distributed Z-scores. For the first 26 lung function variants 
reported11,13,14,48 we showed Stage 2 effect size estimates were comparable with those from inverse 
normally distributed Z-scores in UK BiLEVE (Supplementary Figure 10). Subsequently these Z-scores 
were used for genome-wide association testing using an additive genetic model (SNPTEST v2.5). The 
full genome-wide stage 1 results are available via UK Biobank (http://www.ukbiobank.ac.uk/). 
From each of the three discovery GWAS, signals were selected for follow-up in stage 2 if they met an 
initial threshold of P<5x10-7. Low MAC variants (MAC between 3 and 20), were selected for follow-up 
only if the imputation quality (info) exceeded 0.8. Independence of signals was determined as 
follows: the most strongly associated (P<5x10-7) variant within a 1Mb region was selected as a 
putative signal and then the analysis repeated for that 1Mb region conditioning on the most strongly 
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associated variant. Any variant which then had a conditional P<5x10-7 with the variant being 
conditioned on was then assigned as a secondary putative signal and also included in the conditional 
analysis. This was repeated until no variants with P<5x10-7 remained within the 1Mb region. Results 
were confirmed using a joint conditional analysis (GCTA49) and visual inspection of region plots. 
Previously reported signals were not included in the final list of putative signals to be taken for 
follow-up in stage 2. Where novel signals for different traits were in linkage disequilibrium (r2 > 0.2), 
the variant for the trait with the most significant association was followed up. Due to the extended 
LD structure in the MHC region, conditional analyses and GCTA were run over a 9Mb region 
(chr6:24,126,750-33,126,689). Two pairs of signals previously reported as being independent 
(rs1690985911 and rs1690989814 in PTCH1, and rs3471297916 and rs685642215, in NPNT) were found 
to be correlated in our data. 
Stage 2 – follow-up in independent studies (quantitative lung function) 
Putative novel signals of association from stage 1 were followed up in three independent sets of 
samples (stage 2): i) an independent subset of UK Biobank participants (UK Biobank, n=49,727), ii) a 
population-based consortium (SpiroMeta, n=38,199)15 and iii) UK Households Longitudinal Study 
(UKHLS, n=7,449). Each signal was followed-up only for the trait with which it was most strongly 
associated in Stage 1.  The first tranche of genotype data and imputation output (merged 1000 
Genomes Project Phase 3 and UK10K imputation panel) from UK Biobank was released May 2015 
(http://www.ukbiobank.ac.uk/scientists-3/genetic-data/) and comprised the 49,979 individuals 
originally genotyped for UK BiLEVE (an unrelated subset of 48,943 of which were used as discovery 
in this study) and an additional 102,757 individuals selected at random from the entire UK Biobank. 
From these 102,757 individuals, we initially selected 51,117 samples that had lung function 
measurements (FEV1 and FVC) meeting ATS/ERS criteria and had covariates age, sex, height, 
principal components and smoking status recorded. Following further exclusion of individuals with 
sex mismatches (n=41), individuals of non-European ancestry (based on k-means clustering of 
principal components 1 and 2 with 4 clusters, n=124) and one individual from each pair of related 
samples (KING relatedness > 0.088 [2nd degree], n=1225), a total of 49,727 individuals remained for 
analysis.   
The details of the SpiroMeta consortium analysis (including contributing studies, spirometry details 
and methods) are described elsewhere15. In brief, this was an inverse variance weighted fixed effects 
meta-analysis of 17 studies with imputation to 1000 Genomes Project Phase 1 reference panel. 
Within each study, FEV1, FVC and FEV1/FVC were adjusted for age, age2, sex, height and population 
structure, separately for ever and never-smokers. Inverse normal transformed residuals were then 
tested for association within each smoking stratum assuming an additive genetic effect and then 
meta-analysed. Genomic control was applied to account for residual population structure. We only 
included SpiroMeta meta-analysis results in the meta-analysis in this study if Neffective > 70% (i.e. > 
70% of 38,199), where Neffective is the effective sample size after scaling for imputation quality15. 
Summary statistics of a GWAS of FEV1, FVC and FEV1/FVC in 7,449 individuals were available from 
UKHLS. SNPs were genotyped using the Illumina Infinium HumanCoreExome BeadChip Kit and 
imputed against the same 1000 Genomes Project + UK10K combined imputation panel as used in 
discovery in this study. Association testing was performed separately for ever and never-smokers 
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with covariates age, age2, sex height and ancestry principal components, as for Stage 1. We only 
included UKHLS results in the meta-analysis in this study if imputation info > 0.5 and MAC >= 3. 
Meta-analysis of stage 1 and stage 2 
All meta-analyses were undertaken using fixed effects inverse variance weighting which takes 
directionality of association into account. Effect estimates for all variants followed up in stage 2 were 
meta-analysed across the three stage 2 studies and then the combined result was meta-analysed 
with stage 1 results.  Where the discovery variant was not present in any stage 2 study, a proxy 
(r2>0.8) that was available in all stage 1 and stage 2 studies was used. We report signals with 
association P<5x10-8 in the meta-analysis of stages 1 and 2 as novel signals of association with lung 
function.  
Assessment of stage 1 and stage 2 sample overlap by LD score regression 
LD score regression was used to assess the extent of confounding. Absence of significant confounding 
indicates that factors such as sample overlap and/or population stratification are not evident.”. Pre-
computed LD scores from a European population were used 
(http://www.broadinstitute.org/~bulik/eur_ldscores/), based on genotypes for 1,293,150 HapMap3 
SNPs in samples from the 1000 Genomes EUR population. Association results were filtered 
(INFO > 0.9 and MAF > 1%) before running LD score regression on (i) 3 pairwise meta-analyses of 
results from UK BiLEVE (stage 1) and UK Biobank (stage 2) , UK BiLEVE and SpiroMeta and UK 
Biobank and SpiroMeta; (ii) bivariate analyses of the 3 pairs of cohorts. 
Effect sizes in adults and children 
The effects of variants on lung function in children were also tested in 5062 children from ALSPAC 
(mean age 8.6) and 1220 children from the Raine study (mean age 8.1). Data were available for 73  
of the 97 variants (a proxy variant with r2>0.7 was used for 11 signals) with imputation info >0.8 (71 
variants in ALSPAC and 35 in the Raine study). Association results from the two cohorts were 
combined using inverse variance weighted meta-analysis. A weighted risk score was approximated 
using pooled single SNP results, as described in Dastani et al50, and weights obtained using estimated 
effect sizes from either SpiroMeta 1000 Genomes15 summary data (for SNPs discovered in UK 
Biobank), or from UK Biobank (for SNPs discovered elsewhere). The risk score was tested for the 
three lung function traits: FEV1, FVC and FEV1/FVC.    
Refinement of signals 
A Bayesian method51 was used to fine-map lung function-associated signals to the set of variants 
that were 95% likely to contain the underlying causal variant. This was undertaken for novel signals 
and for previously-reported signals which reached P<10-5 in the stage 1 results.  Following van de 
Bunt et al.52 we set the value of a prior W=0.4 in the approximate Bayes Factor formula. Signals in 
the HLA were not included. 
We re-imputed our 48,493 discovery samples across the HLA (chr6:29,607,078-33,267,103 (b37)) 
using IMPUTE2 v2.3.1 with a reference panel incorporating classical HLA alleles and amino acid 
changes53. The reference panel contained haplotypes for 5225 samples from the type 1 diabetes 
consortium54 (T1DGC) across 8961 biallelic variants comprised of a 5863 directly genotyped biallelic 
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SNPs and 3098 surrogate biallelic variants encoding multiallelic SNPs, indels, classical HLA alleles and 
amino acid changes. Association testing was then undertaken as described for stage 1 for FEV1 and 
FEV1/FVC.  
Effects of lung function associated variants on other traits 
To identify whether the novel and previously reported lung function-associated variants had been 
reported in previous GWAS as associated with traits other than lung function and COPD, we queried 
the GWAS Catalog55 (last update: 13/03/2016, downloaded on 17/03/16) and GRASP56(v2.0, 
downloaded on 17/03/16) for genome-wide significant (P<5x10-8) signals using the 95% credible set 
(if calculated) or all proxy SNPs (r2>0.8) within 2Mb of the top variant in our data. 
Clinical relevance – COPD susceptibility and risk of COPD exacerbations in European and Chinese 
populations 
The effect on COPD susceptibility of up to 95 out of the 97 lung function-associated signals was 
tested in UK Biobank (10,547 COPD cases and 53,948 controls), in the COPD study at deCODE 
Genetics (deCODE COPD study) (1,964 COPD cases and 142,262 controls for single-variant analyses 
and 1,248 COPD cases and 74,700 controls for risk score analyses), in three lung resection studies: 
Groningen, Laval and UBC (310 COPD cases and 332 controls), in the following COPD case-control 
studies: COPDGene Study (2,812 COPD cases and 2,534 controls), Evaluation of COPD Longitudinally 
to Identify Predictive Surrogate End-points (ECLIPSE)(1,736 COPD cases and 176 controls), National 
Emphysema Treatment Trial (NETT) and Normative Aging Study (NAS) (NETT/NAS, 376 COPD cases 
and 435 controls) and the Norway GenKOLS study (Genetics of Chronic Obstructive Lung Disease) 
(854 cases and 805 controls), and the following eMR studies: Mount Sinai BioMe Biobank (BioMe, 
207 COPD cases and 1,817 controls) and Geisinger-Regeneron DiscovEHR Study (DiscovEHR, 1,280 
COPD cases and 13,321 controls).  rs7050036, located in chromosome X, and chr12:114743533, with 
MAF= 0.15%, were not present in most studies and therefore were excluded from these analyses, 
bringing the 97 signals to 95. The effect on risk of COPD exacerbation was additionally tested in the 
Lung Health Study (LHS) (100 COPD exacerbation cases and 4,002 COPD controls) as well as subsets 
of UK Biobank (647 cases and 9,900 controls), COPDGene (557 cases and 2,255 controls), ECLIPSE 
(278 cases and 1,458 controls), NETT/NAS (87 cases and 277 controls), GenKOLS (120 cases and 734 
controls), BioMe (8 cases and 199 controls) and DiscovEHR (774 cases and 472 controls).  Analyses of 
the effect of lung function variants on COPD susceptibility and on risk of COPD exacerbations in a 
Chinese ancestry population were undertaking using the China Kadoorie Biobank prospective cohort 
(CKB) within which data were available for 71 (single variant analyses) or 70 (risk score analyses) of 
the 95 variants (or proxies) for analyses of COPD susceptibility (7,116 COPD cases and 20,919 
controls) and risk of COPD exacerbation (5,292 cases and 1,824 controls). Further details of all 
studies, including case and control definitions are in the Supplementary Note and Supplementary 
Table 20. 
To test the single variant associations with COPD susceptibility and risk of exacerbation, logistic 
regression using age, age2, sex, and height as covariates and assuming an additive genetic effect was 
used. To test the joint effect of these variants, risk alleles in the subset of the 95 signals with data 
available in each study (from 86 to 95) were summed to create an unweighted genetic risk score and 
logistic regression was used to test the effect of the risk score, as a continuous variable, on COPD 
status and COPD exacerbation status (adjusted for age, age2, sex and height). Results, both from 
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single variant and risk scores, were meta-analysed separately for studies where similar study design 
and phenotyping was used: eMR, case-control and lung resection, and results were also meta-
analysed across all studies. Inverse variance weighted meta-analysis was used.  In CKB, analyses 
were adjusted for sex, age, age2, height, region (n=10) and disease status (n=5) and final results were 
GC-corrected based on genome-wide inflation estimates. Heterogeneity was tested using I2(ref 57). 
We calculated odds ratios for spirometrically-defined COPD for weighted risk score deciles in UK 
Biobank (10,547 cases, pre-bronchodilator % predicted FEV1<80% and FEV1/FVC<0.7, and 53,948 
controls, FEV1/FVC>0.7 and % predicted FEV1>80%). The weighting of the risk score was undertaken 
using COPD logOR calculated in studies free of winner’s curse bias (Supplementary Table 21). We 
scaled the logOR, so that the weights added up to 95. 
Population attributable risk fraction calculation 
The population attributable risk fraction (PARF) was calculated using the formula below 
𝑃𝐴𝑅𝐹 =
𝑃(𝐸)(𝑂𝑅 − 1)
1 + 𝑃(𝐸)(𝑂𝑅 − 1)
 
 
where 𝑃(𝐸) is the probability of the exposure, in this case the probability of having more risk alleles 
than those in the lowest decile of the risk score (𝑃(𝐸) =0.9), and the 𝑂𝑅 refers to the odds of having 
COPD for individuals in deciles 2 to 10 of the risk score compared to the odds of having COPD for 
individuals in the lowest decile (decile 1) of the risk score. The 𝑂𝑅𝑠 were calculated separately in 
ever and heavy-smokers using a logistic regression adjusted for age, age2, sex, height and the first 10 
ancestry principal components, and an additional pack-years adjustment for heavy-smokers, and 
were then meta-analysed using inverse variance weighting. Confidence intervals were estimated 
using the formula above with the lower and upper bound of the meta-analysed OR estimated by 
logistic regression. These analyses were run using UK Biobank data and the COPD case definition 
described above: individuals with % predicted FEV1<80% and FEV1/FVC<0.7 were selected as COPD 
cases and those with FEV1/FVC>0.7 and % predicted FEV1>80% were selected as controls. 
Implication of causal genes 
In order to implicate the likely causal gene (or genes) for each of the novel and previously-reported 
signals, we employed functional annotation and analysis of gene expression data. All variants within 
25kb, variants within 500kb and with r2>0.5 of the top SNP at each signal and variants within 1Mb 
and with r2>0.8 with the top SNP were annotated using ENSEMBL’s Variant Effect Predictor (VEP). A 
variant was labelled as deleterious if it was a missense coding variant that was annotated as 
‘deleterious’ by SIFT, ‘probably damaging’ or ‘potentially damaging’ by PolyPhen-2, had a CADD 
scaled score ≥ 20 (CADD_PHRED ≥ 20), or had a GWAVA score > 0.5. The deleterious variants were 
each, in turn, included as a covariate in the association analysis for the top SNP. If inclusion of the 
deleterious variant as a covariate reduced the association signal for the top SNP such that P>0.01, 
that deleterious variant was deemed to explain part of the signal. If annotation (e.g. a coding 
variant) implicated a specific gene, then the gene was classified as a high-priority gene for the 
relevant signal. 
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At each signal, the sentinel SNP and top proxies with r2>0.4 and within 2Mb, no limit on number of 
proxies, were used to query 3 eQTL resources; lung eQTL23,24,58, blood eQTL59 and GTEx60 (artery 
(aorta and tibia), adrenal gland, colon sigmoid, esophagus (gastroesophageal junction and mucosa), 
transformed fibroblasts, lung, spleen, skin (sun exposed lower leg), stomach, testis, thyroid, whole 
blood). A False Discovery Rate (FDR) of 10% was used as a threshold for significance in the lung and 
blood eQTL datasets and 5% in GTEx (due to large number of different tissues and cells, and small 
sample size). A gene was classified as a potential causal gene if the sentinel SNP or proxy (r2>0.9) 
showed significant evidence of being an eQTL signal for that gene. Genes were further classified as 
high-priority genes if the variant most strongly associated with the lung function traits (or a proxy 
with r2>0.9) was also the variant most strongly associated with expression of the gene in one or 
more of the eQTL datasets (i.e. there was co-localisation of the lung function associated SNP and the 
gene expression associated SNP). Due to extended linkage disequilibrium across the MHC region, 
only high-priority genes were identified for the signals in the MHC. 
Pathway analyses 
The genes implicated for each signal (high-priority genes only and all genes) were tested for 
enrichment of gene sets and pathways using ConsensusPathDB61. Pathways or gene sets represented 
entirely by genes implicated by the same association signal were excluded. Pathways or gene sets 
represented by 2 or more genes from the same association signal were flagged. Pathway enrichment 
using all genome-wide P values was undertaken using MAGENTA62 as previously described15. Gene 
sets/ pathways with FDR<5% either including the HLA region or excluding the HLA region were 
reported.  
Tissue specific enrichment of overlap of histone marks 
Two methods were used to test for enrichment of the 97 signals of association with lung function for 
H3K4me1 and H3K4me3 histone marks in up to 127 different tissue and cell types from the ENCODE 
and RoadMap projects39.  
First, enrichment was investigated using a hypergeometric test (as previously described39) using 
SNPs from the GWAS Catalog (hg19, downloaded 02/11/2015) as background. The GWAS Catalog 
was pruned within each contributing GWAS study to retain only SNPs that were at least 1Mb apart 
within that study resulting in 18202 SNPs for further analysis. BEDtools was used to calculate overlap 
with precomputed “gapped peaks” for H3K4me1 and H3K4me3 histone marks and a hypergeometric 
test was used to test the significance of enrichment of the 97 lung function variants compared to the 
background of GWAS Catalog SNPs. Control for multiple testing was undertaken by picking 97 
random variants from the pruned GWAS catalog and repeating the enrichment computation. FDR 
was calculated from 10000 randomizations and FDR=10% was used as a threshold. 
The second method used, GoShifter, calculates overlap enrichment against a null distribution 
generated by locally shifting annotations63. Linkage disequilibrium was calculated using the stage 1 
population. Precomputed “narrow peaks” for H3K4me1 and H3K4me3 histone marks from the 
Roadmap project were used.  Tissues/cell types with overlap enrichment P<0.05 are reported. 
Druggability 
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We searched the ChEMBL database (v21, last update: 01/02/2016, downloaded on 11/02/16) to 
identify whether any of the implicated genes encoded proteins that were targets for approved 
drugs, or drug compounds in development. We additionally searched for genes predicted to interact 
(parameters: STRING score ≥0.90; maximum of 10 interactions per gene) with each of the high-
priority genes32. 
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Figure 1: Genome-wide association results for FEV1 (inner ring), FEV1/FVC (middle ring) and FVC 
(outer ring). Each dot represents a variant, with the X and Y axes corresponding to genomic location 
and -log10 transformed P values respectively. Previously-reported signals are shown in dark blue and 
novel signals are coloured in red. All other signals with a P>5x10-7 (-log10P < 6.3) and/or which did not 
reach genome-wide significance following meta-analysis of stage 1 and stage 2 were coloured in 
grey. Only signals with P<1x10-3 (-log10P > 3) are plotted. The top signals were capped at –log10P=14. 
Grey rings on the y-axis increase by increments of 2 (initial ring corresponding to -log10P=3, then -
log10P=5, etc.); and the outer and inner red rings correspond to the genome-wide significance level 
(P=5x10-8, -log10P=7.3) and the threshold used to select signals for follow up in stage 2 (P=5x10-7, -
log10P=6.3) respectively. Labels show the nearest gene to the novel sentinel variants, with an 
exception made at CDC7 (on chromosome 1) as TGFBR3 was closest to two very close but separate 
signals. Image was created using Circos (v0.64)64. 
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Figure 2 Summary of Bayesian fine-mapping to 95% credible sets for lung function signals. The 95% 
credible set is the set of variants that are 95% likely to contain the underlying causal variant based 
on Bayesian posterior probability.  Following exclusion of signals in the HLA, one chromosome X 
signal and 23 previously-reported signals which did not reach P<10-5 for association with lung 
function in stage 1 of this study, 67 signals underwent Bayesian fine-mapping to identify the 95% 
credible set. A: Numbers of signals fine-mapped to 1, 2-5, 6-10, etc variants. B: Numbers of signals 
for which a single variant accounts for >=95%, 50-95%, 20-50%, etc, of the posterior probability. 
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Figure 3a Forest plot of COPD results for the risk score analysis. Odds ratios per standard deviation 
of the risk score (~6 alleles) are presented for each study.  Studies are grouped according to their 
study design and phenotyping: “eMR”, electronic medical records, which used ICD codes to define 
COPD (DiscovEHR also used spirometry to refine the COPD definition); “case-control”, COPD case-
control, which used post-bronchodilator spirometry to define COPD; “lung resection cohort”, which 
used a combination of pre and post-bronchodilator spirometry to define COPD; the Icelandic 
Biobank, deCODE, where cases were selected from a population based study and a study of COPD 
patients and defined using a spirometric definition, controls were selected as individuals within the 
cohort that were not known cases (no spirometric definition was used for controls); and UK Biobank, 
which used spirometry to define both COPD cases and controls. UK Biobank is separated into UK 
BiLEVE, which was the discovery population for 48 of the variants included in the risk score (43 
discovered in this analysis and 5 in 16) and the remaining UK Biobank labelled “UK Biobank”. Details 
about study description and COPD definitions are provided in the Supplementary Note. These 
groups are separated in the graph by dotted lines and meta-analysis results per study design group 
are presented, as well as for the overall meta-analysis. 
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Figure 3b  
Odds ratios for spirometrically-defined COPD for weighted genetic risk score deciles in UK Biobank 
(10,547 cases, pre-bronchodilator % predicted FEV1<80% and FEV1/FVC<0.7, and 53,948 controls, 
FEV1/FVC>0.7 and % predicted FEV1>80%, weights derived from non-discovery populations). For 
each decile, odds ratios were obtained using a logistic regression adjusted for age, age2, sex, height, 
smoking status, pack-years and the first 10 ancestry principal components. The OR comparing the 
10th and the 1st decile in ever-smokers only was 3.35 (95% CI 2.93 to 3.84) and in never-smokers only 
was 4.27 (95% CI 3.61 to 5.06).  
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Table 1 Genes implicated as high-priority genes for novel genome-wide significant and previously-
reported signals using expression data and functional annotation. #Variant did not reach P<5.15x10-4 
(Bonferroni corrected P value for 97 tests) in this study for any trait. *Gene implicated as it 
contained a deleterious variant (Supplementary Table 14); all other genes implicated by co-
localisation of GWAS and eQTL signal. (*) implicated by both co-localisation of eQTL and GWAS, and 
a deleterious variant. All 234 genes implicated are listed in Supplementary Table 15. 
Genome-wide 
significant trait 
(additional traits 
with P<5.15x10-4) 
Variant ID (position b37) Nearest gene(s) High-priority genes 
Novel signals 
FEV1/FVC (FVC) rs17513135 (chr1:40,035,686) LOC101929516 PABPC4 
FEV1/FVC (FEV1) rs6688537 (chr1:239,850,588) CHRM3 CHRM3 
FEV1/FVC (FEV1) rs2811415 (chr3:127,991,527) EEFSEC RUVBL1 
FEV1/FVC (-) rs13110699 (chr4:89,815,695) FAM13A FAM13A 
FEV1 (FVC, FEV1/FVC) rs3839234 (chr5:148,596,693) ABLIM3 GRPEL2, ABLIM3 
FEV1/FVC (FEV1) rs10515750 (chr5:156,810,072) CYFIP2 ADAM19 
FEV1/FVC (FEV1) rs200003338 (chr6:31,556,155) LST1 MICB*, MICA* 
FEV1/FVC (FEV1) rs10246303 (chr7:7,286,445) C1GALT1 C1GALT1 
FVC (FEV1) rs10870202 (chr9:139,257,411) DNLZ INPP5E, CARD9 
FVC (FEV1) rs7095607 (chr10:69,957,350) MYPN MYPN* 
FEV1 (FVC) rs2509961 (chr11:62,310,909) AHNAK ROM1, EML3, MTA2, 
GANAB, C11orf83* 
FEV1/FVC (-) rs59835752 (chr17:28,265,330) EFCAB5 EFCAB5, CRYBA1, SSH2, 
SLC6A4 
FEV1/FVC (FEV1) rs11658500 (chr17:36,886,828) CISD3 CISD3* 
FEV1 (FVC) rs72448466 (chr20:62,363,640) ZGPAT LIME1 
 Previously-reported signals 
FEV1 (FVC) rs6681426 (chr1:150,586,971) MCL1-ENSA GOLPH3L 
FEV1/FVC (-) rs4328080 (chr1:219,963,088) LYPLAL1-RNU5F-1 SLC30A10 
FEV1 (FVC, FEV1/FVC) rs2571445 (chr2:218,683,154) TNS1 TNS1* 
FEV1/FVC (-) rs10498230 (chr2:229,502,503) SPHKAP-PID1 SPHKAP 
FVC (FEV1) rs1595029 (chr3:158,241,767) RSRC1 RSRC1 
FEV1 (FVC, FEV1/FVC) rs10516526 (chr4:106,688,904) GSTCD INTS12, GSTCD, NPNT 
FEV1/FVC (FEV1, FVC) rs34712979 (chr4:106,819,053) NPNT NPNT 
FEV1/FVC (FEV1) rs138641402 (chr4:145,445,779) GYPA-HHIP-AS1 HHIP 
FEV1/FVC (-) rs153916 (chr5:95,036,700) SPATA9-RHOBTB3 RHOBTB3 
FEV1/FVC (FEV1) rs1990950 (chr5:156,920,756) ADAM19 ADAM19 
FEV1 (FVC, FEV1/FVC) rs34864796 (chr6:27,459,923) ZNF184-LINC01012 OR2B2* 
FEV1/FVC (FEV1) rs2857595 (chr6:31,568,469) NCR3-AIF1 MICB* 
FEV1/FVC (-) rs2070600 (chr6:32,151,443) AGER AGER(*) 
FEV1 (FVC, FEV1/FVC) rs114544105 (chr6:32,635,629) HLA-DQB1-HLA-DQA2 HLA-DQB1*, APOM, 
RNF5 
FEV1/FVC (FEV1) rs113096699 (chr6:142,745,883) GPR126 GPR126 
FEV1/FVC (-) rs148274477 (chr6:142,838,173) GPR126-LOC153910 GPR126* 
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FVC (FEV1) rs10858246 (chr9:139,102,831) QSOX2 QSOX2 
FVC (FEV1) rs2348418 (chr12:28,689,514) CCDC91 FLJ35252 
FEV1/FVC# (-) rs11172113 (chr12:57,527,283) LRP1 LRP1 
FEV1# (-) rs7155279 (chr14:92,485,881) TRIP11 ATXN3 
FEV1# (-) rs117068593 (chr14:93,118,229) RIN3 RIN3(*) 
FEV1/FVC (FEV1) rs10851839 (chr15:71,628,370) THSD4 THSD4 
FEV1/FVC (-) rs12447804 (chr16:58,075,282) MMP15 MMP15 
FEV1/FVC (FEV1) rs3743609 (chr16:75,467,021) CFDP1 TMEM170A, BCAR1, 
CFDP1 
FEV1 (FVC, FEV1/FVC) rs35524223 (chr17:44,192,590) KANSL1 KANSL1(*), MAPT(*), 
ARL17B, ARL17A, 
LRRC37A4, NUDT1, 
LRRC37A, CRHR1, 
LRRC37A2, ARHGAP27, 
FMNL1, PLEKHM1, 
WNT3, NSF, SPPL2C* 
FEV1 (FVC) rs7218675 (chr17:73,513,185) TSEN54 CASKIN2, TSEN54* 
FEV1/FVC (-) rs113473882 (chr19:41,124,155) LTBP4 LTBP4* 
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